Clinical trial
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in…
NCT00436826 · EMD Serono Research & Development Institute, Inc., Industry · Completed
Key facts
| NCT number | NCT00436826 |
|---|---|
| Title | A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) |
| Official title | A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease |
| Acronym | ONWARD |
| Lead sponsor | EMD Serono Research & Development Institute, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Cladribine, Placebo, Interferon-beta (IFN-beta) |
| Enrollment | 172 |
| Start date | Nov 30, 2006 |
| Primary completion | Sep 30, 2011 |
| Completion | Mar 31, 2012 |
| First posted | Feb 19, 2007 |
| Last update posted | Oct 12, 2020 |
| Countries | Italy, Russia, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: